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Abstract: Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition 
which is characterized by a decrease in sexual desire that causes marked personal distress and/
or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to 
treat is due to the large number of potential causes and contributing factors. Indeed, a balanced 
approach comprising both biological and psycho-relational factors is mandatory for accurate 
diagnosis and tailored management in clinical practice. There are currently no approved 
pharmacological treatments for premenopausal women with HSDD, while transdermal testos-
terone is approved in Europe for postmenopausal women who experience HSDD as a result 
of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual 
response during the entire reproductive life span of women is crucial, a better understanding 
of the neurobiological basis of sexual desire supports the idea that selective psychoactive 
agents may be proposed as nonhormonal treatments to restore the balance between excitatory 
and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal 
clinical approach to HSDD remains to be established in term of efficacy and safety, and   further 
research is needed to develop specific hormonal and nonhormonal pharmacotherapies for 
individualized care in women.
Keywords: sexual desire, distress, testosterone, psychoactive drugs, psychosexual 
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What is hypoactive sexual desire disorder?
Low sexual desire is a very common symptom in women of any age with potential 
negative consequences on quality of life and well-being.1–3 The American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR)4 
and the World Health Organization’s International Classifications of Disease-10 
(ICD-10)5 established that the definition of hypoactive sexual desire disorder (HSDD) 
should include not only the lack or absence of sexual fantasies or desire for any form of 
sexual activity, but also the presence of personal distress and/or interpersonal difficul-
ties. Generalized acquired HSDD is the most common diagnosis when the condition is 
not dependent on a specific situation or relationship and has developed after a period 
in which sexual desire and sexual functioning were considered normal. A diagnosis of 
HSDD may be comorbid with another sexual dysfunction, but it cannot be exclusively 
attributed to another medical condition or to the physiological effects of a medication.6,7 
The very recent recommendations from the 3rd International Consultation on Sexual 
Medicine (ICSM)8,9 pointed out that the definition of HSDD needs a revision because 
there is a great heterogeneity among women in the sexual response models they identify International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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with,10 and new criteria have been   proposed for consideration 
in the forthcoming DSM-V .11
Key findings from large population-based studies (the 
Prevalence of Female Sexual Problems Associated with 
Distress and Determinants of Treatment Seeking [PRESIDE] 
and the Women’s International Study of Health and Sexuality 
[WISHeS]) analyzing the prevalence of sexual symptoms 
associated with distress across the United States (US) and 
Europe, clearly indicate that female sexual dysfunction (FSD) 
is a real burden for many women and approximately one in 
ten women may receive a diagnosis of HSDD.3 The PRESIDE 
study was conducted with more than 31,000 women aged 
over 18 years in the US and documented that the prevalence 
of sexual distress symptoms, including HSDD which was the 
most commonly reported, peaked in middle-aged women. 
Between 18 and 44 years of age the prevalence of HSDD 
was 8.9%, while it was 12.3% between 45–64 years and 
7.4% in women 65 years old or older. In addition, the odds 
of distressing desire problems increased with worsening of 
self-assessed health and were approximately 20% higher in 
postmenopausal than in premenopausal women.3 WISHeS 
involved over 3,500 women between 20–70 years of age, 
resident in the US and in four Western European countries. 
The prevalence of HSDD ranged from 6%–13% in Europe 
and 12%–19% in the US, and the proportion of women with 
low desire associated with distress was significantly higher 
in younger women in comparison with older women.12,13 
Surgically menopausal women were significantly more likely 
to experience HSDD than their age-matched counterparts 
who did not have surgery, and a younger age was a risk fac-
tor for being emotionally and psychologically distressed by 
low desire, with a less active sex life and decreased sexual 
and relationship satisfaction.14 The negative personal issues 
associated with decreased sexual interest include feeling 
less feminine, feeling like a sexual failure, low self-esteem, 
insecurity, inadequacy and letting partner down.12,13 More-
over, a higher percentage of women with low sexual desire 
feel frustrated, concerned, unhappy, disappointed, hopeless, 
troubled, ashamed, and bitter, compared with women with 
normal desire.12,13 Finally, the distress is positively associ-
ated with depression15 and it is particularly evident when a 
current partner is present.16 Women who are better able to 
communicate their sexual needs report less distress associated 
with low sexual function.15
That being so, it is a duty of health care providers to 
address the issue of sexuality routinely in clinical practice 
and to recognize the distress eventually associated with 
sexual dysfunction. However, it is still quite difficult to 
engage in sexual conversation because of many barriers and 
  misconceptions, including the idea that sexual problems are a 
normal part of aging, menopause, long relationship, etc, and 
do not deserve specific treatments.17,18 In addition, the mul-
titude of determinants of sexual desire across the life cycle 
and the difficulties in establishing the level of discrepancy 
between expected and current desire in a specific relational 
context bring about the idea that HSDD is a condition difficult 
to treat. On the other hand, personal experiences and cultural 
norms may modulate the clinical relevance of sexual symp-
toms and the level of response to specific treatments.19
Here we attempt to summarize the most common thera-
peutic strategies available to help women with HSDD in a 
balanced perspective by integrating basic counseling and 
medical and/or psychosocial interventions, as appropriate. 
By no means is it either a systematic review or a   meta-analysis 
of all the available evidence in this complex field, and it 
merely reflects the opinion of the authors on addressing the 
various facets of HSDD in clinical practice.
Contributors to HSDD
An accurate diagnosis of HSDD is crucial to understand 
the potential causes and, eventually, to establish treatment 
strategies with drugs.20 On the other hand, being aware of 
the complexity of contributors driving the healthy sexual 
response cycle, intrapersonal and interpersonal factors need 
to be addressed and adequately treated with tailored counsel-
ing and psychosexual approaches.21
A recent conceptualization of HSDD implies that such 
sexual dysfunction may be the result of the inability of the 
neuroendocrine circuitries to integrate the complex nature 
of sexual response encompassing physiological, psycho-
logical, emotional, and/or relationship components.22–24 
Current research suggests that neurotransmitters, strongly 
influenced by sex hormones (estrogen, androgens, and even 
progesterone), play a key role in modulating sexual desire. 
When an imbalance between the dopaminergic system (which 
increases sexual desire and excitement) and norepinephrine 
system (which affects arousal and orgasm) occurs, women 
may feel unable to begin the sexual response cycle. In addi-
tion, an overactive serotoninergic system can decrease desire 
and delay orgasm. The net balance between stimulating and 
inhibitory factors brings about the ability to experience 
sexual desire and eventually to engage in sexual activity. 
Other mediators have been postulated to play a critical role 
in women’s sexuality, including oxytocin, melanocortins, 
opioid, and endocannabinoid systems. Sexual excitation can 
be primed internally by sex hormone actions or externally International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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by sexual incentives or substances that activate excitatory 
  neurochemical systems. However, when endogenous inhibi-
tory mechanisms are tonically activated by situational vari-
ables, such as stress and fatigue, and/or by compounds that 
reinforce inhibition (ie, selective serotonin reuptake inhibitors 
[SSRIs]) or, alternatively, sexual excitatory mechanisms are 
endogenously blunted, as it may occur in some hormonal 
and/or metabolic conditions, several amounts of FSD may 
be present and sexual symptoms may be co-occurring in the 
same woman.25 Therefore, even though psychorelational 
issues and sociocultural factors should always be ruled 
out, there is no doubt that biological aspects, including sex 
hormone deficiency, as well as other medical conditions and 
medications which may cause a neuroendocrine imbalance, 
play a major role in the clinical manifestation of sexual 
problems that induce personal distress and, therefore, may 
require intervention.26,27 Indeed, the iatrogenic removal of 
both ovaries, which may occur well before the age of natural 
menopause, is characterized by the effects of acute estrogen 
and even androgen deprivation in several domains of sexual 
function (desire, arousal, lubrication, orgasm, satisfaction) 
and has been significantly associated with HSDD and severity 
of other menopausal symptoms such as vaginal dryness.28–30 
Following bilateral oophorectomy, both premenopausally and 
postmenopausally, there is a sudden 50% fall in circulating 
testosterone (T) levels which have been associated with the 
so-called androgen-insufficiency syndrome; an increasingly 
accepted clinical entity comprising specific symptoms such 
as low sexual desire, persistent and inexplicable fatigue, 
blunted motivation and a general reduced sense of well-
being.31 It is also known that T significantly declines with 
age, independently from the menopausal transition, because 
of a progressive reduction of adrenal production. Menopausal 
women have decreased androgens compared to younger 
women but the aging ovary is still capable of producing 
a variable amount of androgens with relevant effects on 
women’s general and sexual health depending on the bio-
availability of sexual hormones within target tissues.32,33 On 
the other hand, a major source of sex hormones in women 
after menopause is the inactive precursor steroid dehydroepi-
androsterone (DHEA) of adrenal origin, which is converted 
into active androgens and/or estrogens in specific peripheral 
tissues.34 That being so, data collected in a community-based, 
cross-sectional study of 1423 Australian women (age range: 
18–75 years) failed to demonstrate a correlation between 
plasma T   levels35 and sexual symptoms. In addition, no   cut-off 
level for a normal range of T has been agreed on and the 
lack of consensus on the definition of low T levels depends 
namely on the   difficulties with sensitive assays of total and 
free T in women.32 In the same Australian study sample, an 
association between plasma dehydroepiandrosterone sulphate 
(DHEAS) levels below the 10th percentile and low scores on 
several sexual function domains was found.34 However, the 
majority of women with low DHEAS levels did not report 
low sexual function, confirming other findings reporting a 
wide range of androgen circulating levels in fertile women 
with normal sexual function.36
Even women with natural menopause report a high rate 
of FSD with a variable prevalence across studies depending 
on several factors (ie, sample, design, menopausal symp-
toms, sociocultural background, etc).37 The longest duration 
population-based study, the Melbourne Women’s Midlife 
Health Project, found a significant decrease of women’s 
desire, arousal, orgasm, and frequency of sexual activity, 
and a significant increase in vaginal dryness/dyspareunia, 
with a rate of sexual dysfunction that ranged from 42% to 
88% throughout the menopausal transition.38,39 However, 
only 17% of women were sexually distressed, supporting 
the notion that sexual symptoms are quite normal at meno-
pause and they are clinically relevant only when exerting a 
significant impact on intrapersonal and interpersonal well-
being.40 Indeed, both age and declining estradiol (E2) levels 
had significant detrimental effects on sexual functioning, 
desire, and sexual responsiveness (arousal, sexual pleasure, 
and orgasm). Interestingly enough, by investigating the rela-
tive effects of hormonal and relationship factors in sexual 
function during the natural menopausal transition, it has 
been demonstrated that the best predictors of sexual function 
were prior level of sexual function, change in partner status, 
feelings for partner, and E2 level (R2 = 0.65). Moreover, the 
minimum effective dose of E2 needed to increase sexual 
response by 10% (700 pmol/L = 190.7 pg/mL) is twice that 
needed to decrease dyspareunia, supporting the notion that 
other hormonal-mediated mechanisms, modulating physi-
cal and mental well-being more broadly, are significantly 
involved in sexual functioning across the menopause.41 To 
further reinforce the idea that HSDD is a multidimensional 
condition, a cross-sectional study conducted in a sample of 
US and European women between 18 and 65 years of age 
reported that women suffering from characteristics of HSDD 
have more negative patterns of partner interactions.42 Finally, 
the PRESIDE study identified current depression, anxiety, 
thyroid problems, and urinary incontinence as the medical 
conditions positively associated with HSDD, but many other 
chronic diseases and related treatments may be significantly 
associated with distressing low sexual desire, including International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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the use of antihormones, chemotherapies and recreational 
substances.3
From a practical point of view, the diagnosis of HSDD 
should encompass the major biological causes such as states 
of sex hormone deficiency, especially low androgens, mood 
disorders, including anxiety and depression, and many clini-
cal conditions and related medications with a potential impact 
on women’s sexual function. On the other hand, intrapersonal 
and interpersonal issues, including partner’s general/sexual 
health and duration/quality of the relationship, and sociocul-
tural aspects in the context of the life cycle stage should be 
taken into account for a comprehensive approach.
That notwithstanding, the possibilities of treating HSDD 
are multifaceted and should include the combination of 
pharmacological treatments able to maximize biological 
signals driving the sexual response, and individualized 
psychosocial therapies in order to overcome personal and 
relational difficulties.43,44
Current treatments for HSDD
The complexity of factors involved in HSDD and the poor 
awareness that low desire associated with distress is a medi-
cal condition, have slowed down the development of drugs 
specifically designed for women with FSD. The investiga-
tion on FSD is, indeed, a rapidly evolving area in which 
definitions and models for women’s sexual functioning are 
being continually reviewed and revised.7 A large amount 
of literature has been devoted to the role of sex hormones, 
especially androgens, in the treatment of HSDD in post-
menopausal women.45,46 However, a better understanding of 
physiology and pathophysiology, together with the recogni-
tion of the most appropriate inclusion and exclusion criteria 
for FSD trials and the development of sensitive diagnostic 
instruments to identify the main outcome measures suitable 
for the evaluation of drug interventions, have stimulated 
progression in this area of research both in premenopausal 
and postmenopausal women.19,26,47
The impact of endocrine factors in women’s sexual func-
tion have been recently revised48 and, even though the distinct 
effects of estrogens and androgens on sexual desire, arousal, 
and receptivity are still not completely understood, it is clear 
that the endocrine milieu plays a critical role in setting the 
threshold to sexual stimuli at least in some individuals.45,46
Hormone therapy (HT) with estrogen alone (ET), as it is 
indicated in hysterectomized menopausal women, and with 
estrogen-progestin (EPT), as it is currently used in meno-
pausal women with intact uterus, has been the   first-line 
hormonal treatment for women reporting menopausal 
symptoms (mainly hot flushes) across menopausal 
transition and beyond. In addition, systemic ET/EPT, and 
even local ET, may be an effective treatment for vulvo-
vaginal atrophy with a potential positive effect on sexual 
function due to the improvement of lubrication. However, 
in spite of the reduction of dyspareunia, some women 
with FSD remain unresponsive because ET/EPT does not 
consistently increase sexual desire or activity, especially 
in surgical menopause.49,50 Indeed, the first randomized 
clinical trial suggesting that sexual desire problems 
respond better to androgen therapy (AT), and even better to 
combined AT/ET, rather than to ET alone, was conducted 
by Greenblatt et al in 1950 in a sample of ovariectomized 
women.51 Since then, several studies have been conducted 
demonstrating that androgens may play a role in enhanc-
ing sexual desire and arousal in women, but these early 
findings were often related to supraphysiological doses 
of testosterone.46 Two Cochrane reviews have recently 
examined the benefits and risks of T plus EPT versus EPT 
alone for peri- and postmenopausal women by including 
35 studies with 4,768 participants.52,53 The majority of the 
trials with several T regimens (oral tablets, intramuscular 
injections, subcutaneous implants, transdermal patches/
gels) included only postmenopausal women, both naturally 
and surgically menopausal. The median study duration was 
6 months (range 1.5–24 months) and many methodological 
limitations were outlined. However, the pooled estimate 
from the clinical trials suggested that the addition of T to HT 
regimens improved sexual function scores and number of 
total satisfying sexual episodes in postmenopausal women. 
Beneficial effects were seen for the composite sexual func-
tion score and domains of sexual activity, coital frequency, 
responsiveness, and desire.
Adverse effects included increased incidence of excess 
hair growth and acne and decreases in high-density lipoprotein 
(HDL) cholesterol levels with oral T therapy, but not with 
transdermal T treatment which bypasses hepatic metabolism. 
Discontinuation from treatment was similar between groups. 
There was insufficient evidence of a treatment effect for 
perimenopausal/premenopausal women or for other outcomes 
examined, including well-being, fatigue, menopausal symp-
toms, cognition, body composition, and bone health. Another 
large review of safety data also concluded that, except for 
hirsutism and acne, the therapeutic administration of T in 
physiologic doses was safe for up to several years.54
A series of double-blind, randomized, placebo-controlled 
studies examined the efficacy and safety of a transdermal 
T patch (300 µg) in postmenopausal women with HSDD.55,56 International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Two multicenter trials evaluated 24 weeks of T patch 
  treatment in over 1,000 surgically menopausal women with 
HSDD receiving concomitant estrogen therapy. At baseline, 
women reported approximately three satisfying sexual epi-
sodes in 4 weeks, with a mean increase of approximately 
two events in T-treated women, compared with an increase 
of one satisfying event with placebo. A 450 µg patch, how-
ever, did not confer benefit beyond placebo suggesting the 
lack of a dose response effect of the T patch.57 In addition 
to increased sexual activity, significant improvements were 
seen in all domains of sexual function in T-treated women 
compared with placebo, including desire, arousal, orgasm, 
pleasure, concerns, responsiveness, sexual self-image, 
and distress. Despite the low absolute change in satisfying 
sexual events, the degree of benefit seen with T therapy 
in these studies was “clinically meaningful” to women.58 
Adverse event profiles were similar except for a higher 
incidence of unwanted hair growth in T-treated women. 
Other androgenic adverse events such as acne, alopecia or 
voice deepening were more common in T-treated women, 
though not statistically significant. The safety and efficacy 
of transdermal T (300 µg) for 24 weeks was also studied in 
a double-blind, placebo-controlled, randomized trial of 549 
naturally menopausal women with HSDD on concomitant 
ET. Total satisfying sexual episodes increased significantly 
from baseline in T-treated women compared with placebo 
(2.1 episodes vs 0.5).59 Small but statistically significant 
improvements were also seen in all domains of sexual func-
tion assessed, including sexual desire and personal distress. 
As almost all studies of T therapy were performed in the 
setting of concurrent estrogen administration, a double-
blind, placebo-controlled trial examined the safety and 
efficacy of T treatment for HSDD in 814 postmenopausal 
women not receiving ET.60 Women were randomized 
to 150 or 300 µcg of transdermal T per day or placebo; 
efficacy was measured to week 24 and safety to week 52. 
The increase in the 4-week frequency of satisfying sexual 
episodes was significantly greater in the women receiving 
300 µg T per day compared with placebo (2.1 episodes 
vs. 0.7), although not in the group receiving the lower T 
dose (150 µcg per day). Both doses resulted in significant 
increases in desire and decreases in distress compared with 
placebo. Androgenic adverse events, principally unwanted 
hair growth, was higher in the women receiving 300 µcg 
T compared with placebo, although rates of acne, alopecia 
and voice deepening were similar among the three groups. 
Vaginal bleeding was more common in the 300 µcg T group, 
although no cases of endometrial hyperplasia or carcinoma 
were diagnosed. There were no differences between groups 
in vital signs or weight, serum lipid or lipoprotein profiles, 
measures of carbohydrate metabolism, liver function, or 
other laboratory tests. Breast cancer was diagnosed in 
four women who received T, as compared with none who 
received placebo, but such evidence was not statistically 
meaningful. T has been studied also in a small group of pre-
menopausal women (n = 31, age range: 30–45 years) with 
HSDD who were randomized to treatment with a T cream 
(10 mg/d) versus placebo in a double-blind crossover study 
for 12 weeks with a 4 week washout. T treatment resulted 
in statistically significant improvements in the composite 
scores and many subscale scores to measure sexual function 
and well-being.61
That being so, the European Medical Authority 
(EMEA) approved the transdermal T patch for surgi-
cally menopausal women with HSDD on concurrent ET, 
but T replacement therapy in women is still an ongoing 
debate. Indeed, in the US there is a combination of oral 
E + methyltestosterone (MT) approved for the treatment 
of moderate to severe vasomotor symptoms but no FDA-
approved androgen treatments for HSDD. However, the 
increased off-label use of T62 supports the evidence that 
women are in need of medical therapies to relieve sexual 
dysfunction, and doctors feel positive about the safety and 
effectiveness of T formulations, at least on a short-term 
basis.63,64 Guidelines and position statements differ quite 
significantly, creating a therapeutic dilemma.65 In 2005, 
The North American Menopause Society concluded that 
postmenopausal women with decreased sexual desire asso-
ciated with distress and with no other identifiable cause may 
be candidates for T therapy.66 Treatment is contraindicated 
in women with breast or uterine cancer, or in those with 
cardiovascular or liver disease. Women need to be informed 
of all potential risks and that data on long-term use are 
lacking, suggesting administration at the lowest dose for the 
shortest time. On the other hand, in 2006. The Endocrine 
Society concluded that although there is evidence for short-
term efficacy of T in selected populations, generalized use 
of testosterone by women is not recommended due to inad-
equate indications for treatment and the lack of evidence 
of safety in long-term studies.67 Many commentaries have 
been written to critically discuss the topic, concluding that 
the decision to treat postmenopausal women with HSDD 
with T is mainly based on clinical judgment, after an 
informed consent regarding the unknown long-term risks 
of androgen treatment in women, namely cardiovascular 
diseases and breast cancer.48International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Another potential option of HT for HSDD is tibolone, 
a synthetic steroid not available in the US, which is metabo-
lized to two estrogenic metabolites, 3α and β, becoming 
active in target tissues. Tibolone itself and its 3β metabolite 
is also converted to a ∆4-isomer which can activate both the 
progesterone and androgen receptor. Tibolone lowers sex 
hormone-binding globulin (SHBG) and increases circulating 
free testosterone, adding to its androgenicity. Apart from alle-
viating postmenopausal vasomotor symptoms and improving 
urogenital atrophy, some studies suggest that tibolone is 
effective in postmenopausal women with symptoms of sexual 
dysfunction.45,68 In a recent multicenter, double-blind, ran-
domized, clinical trial, tibolone improved sexual wellbeing in 
postmenopausal women with low libido with improvements 
in desire arousal, satisfaction, and receptiveness, compared 
to those receiving transdermal estrogen-progestin therapy.69 
Even with tibolone some concerns have been raised about 
long-term use and risk of cardiovascular disease and/or 
breast cancer.48
There is conflicting evidence over the efficacy of DHEA 
(an androgen classed as a pro-hormone because it can be 
converted into a variety of biologically active androgens and 
estrogens)70 in improving sexual function, and at the present 
time the use of DHEA is not recommended in women with 
HSDD.48
Plant-derived and herbal remedies are a very popular 
alternative to medical treatments, but the real effectiveness 
in improving sexual function in women is not proven.71 For 
example, Ginkgo biloba extract (GBE) which facilitates blood 
flow, influences nitric oxide systems, and has a relaxant effect 
on smooth muscle tissue, failed as an antidote to antidepressant-
induced sexual dysfunction.72 The long-term effects of GBE 
on sexual function have been recently assessed in 68 sexually 
dysfunctional women who were randomly assigned to 8 weeks 
treatment of either (1) GBE (300 mg/daily), (2) placebo, (3) 
sex therapy which focused on training women to attend to 
genital sensations, or (4) sex therapy plus GBE. Interestingly 
enough, when combined with sex therapy, but not alone, long-
term GBE treatment significantly increased sexual desire and 
contentment beyond placebo.73
To combine biomedical and psychosocial interventions is, 
indeed, the best approach to any kind of FSD to provide an 
optimal outcome. Basic sexual counseling should be always 
part of the consultation to provide information and to promote 
communication about sexual issues.74
As far as HSDD is concerned, individual or couple-
based psychosexual therapy, with the additional counseling 
of the partner, may be proposed, even though most of 
the psychotherapy literature reported that HSDD is often 
treatment refractory.43 There is some evidence to support the 
efficacy of cognitive behavioral approaches in HSDD.75,76 
However, the majority of psychosocial interventions have 
been conducted in premenopausal women and there is 
still a paucity of well-controlled studies in the field due to 
methodological problems in sex therapy outcome studies.77
Emerging treatments in the 
management of HSDD
The possibilities to treat HSDD are scarce, with transdermal 
T being the only approved treatment for postmenopausal 
women with FSD. Some authors with peculiar expertise in 
the field of FSD believe that the reason for the paucity of 
drugs under investigation is related more to the standards for 
clinical trials in women than to the potential efficacy of the 
drugs themselves.78 However, it is mandatory to develop new 
safe and effective hormonal and nonhormonal treatments of 
HSDD that can be approved by the health authorities both in 
pre- and postmenopausal women. We have mentioned before 
that research in laboratory animals and clinical observation 
in humans has suggested that acting on the balance of neu-
rotransmitters, mainly increasing dopaminergic activity and 
decreasing serotoninergic activity, may have a prosexual 
effect.25 The picture is, of course, much more complicated 
that this simple statement and individual receptor subtypes, 
namely serotoninergic receptors 5HT1a and 5-HT2, have to 
be taken into account in order to explain different effects of 
specific drugs on sexual responsiveness. In addition, for most 
of the neuroactive compounds that have been investigated 
over time, mainly in premenopausal women, to avoid the 
potential impact of postmenopausal hormonal deficiency, 
there is a lack of well-controlled studies on the real efficacy 
and safety in clinical practice.43 That being so, it is worth 
mentioning here the mild to moderate prosexual effect of 
buproprion, a compound with both dopamine and norepi-
nephrine reuptake inhibition, in some women with HSDD.79 
Even apomorphine, a nonselective dopaminergic receptor 
agonist, has been postulated to be effective in premeno-
pausal women affected by HSDD and arousal disorder. In a 
placebo-controlled pilot study including 62 volunteer women 
(26–45 years of age) daily apomorphine SL (2 or 3 mg) 
may improve the sexual life of women affected by sexual 
difficulties.80 However, additional studies are needed to better 
establish the safety profile of the drug before recommending 
it in clinical practice.
On the basis of the long-term clinical experience with 
sexual side-effects of many antidepressants,   flibanserin, International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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a novel centrally acting compound with both 5HT2 
  antagonism and 5HT1a agonism81 is currently investigated 
to assess safety and efficacy in a large phase III clinical 
trial program (the Bouquet study program) involving over 
5,000 premenopausal women with generalized acquired 
HSDD, recruited both in North America and Europe. In 
addition to binding to 5-HT1A and 5-HT2A receptors, fli-
banserin binds with moderate affinity to the dopamine D4 
receptors. Preliminary data (Boheringer Inghelheim, data on 
file, 2009) have shown that flibanserin 100 mg once-daily, 
taken at bedtime, is a well-tolerated potential treatment for 
HSDD in premenopausal women, while no data are pres-
ently available on the use of flibanserin in postmenopausal 
women.
In conclusion, the recognition that HSDD is a common 
condition that deserves not only cognitive behavioral therapy 
or other psychosocial approaches but also pharmacological 
treatments capable of increasing sexual desire and sexual 
function, while significantly decreasing the associated dis-
tress, represents a critical step in the field of FSD. Even 
though the ideal clinical approach to HSDD remains to be 
established, the use of androgen therapy represents a suit-
able option for postmenopausal women. Further research 
is needed to develop specific hormonal and nonhormonal 
pharmacotherapies for individualized care in women during 
the entire reproductive life cycle.
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